Health Care

Headline News

Abbott Labs (ABT)

Abbott's New Cancer Test

A new diagnostic tool physicians can use to monitor patients for the most common form of ovarian cancer may soon be available in the United States. Abbott’s ARCHITECT HE4 assay uses a simple blood test to help in monitoring for the recurrence or progression of epithelial ovarian cancer. If approved, this important immunoassay would be the first automated HE4 test available in the United States.
"The ability to monitor the recurrence or progression of ovarian cancer is a critical part of patient care. The ARCHITECT HE4 assay has the potential to be a powerful tool for both physicians and patients in the management of the disease," said Michael Warmuth, senior vice president, diagnostics, Abbott.

Feb 9 · 2:36:00 PM · Source: Company Press Release
Track · email · face · Twitter · digg · COMMENTS
by Rich Pike

Johnson & Johnson (JNJ)

J&J Recalls Tylenol Arthritis Caplet

Johnson & Johnson is expanding a voluntary recall of Tylenol Arthritis Caplets due to consumer reports of a moldy smell that can cause nausea and sickness.
Johnson & Johnson had recalled five lots of the product last month after consumers complained of a musty, mildew-like odor that triggered nausea, stomach pain, vomiting and diarrhea. The health care company said the odor results from trace amounts of a chemical called 2,4,6-tribromoanisole. That chemical is believed to result from the breakdown of another chemical used to treat wooden pallets that transport and store packaging materials. To date, the side effects, which also include vomiting and diarrhea, have been "temporary and non-serious," although the health effects of the compound have not been studied.

Dec 29 · 1:59:00 PM · Source: MSN Money
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Pfizer (PFE)

Pfizer Buys Rights To Gaucher Drug

Pfizer said Tuesday it had reached an agreement to license the worldwide rights to a treatment for Gaucher disease, a rare genetic disorder, from Protalix, an Israeli biotechnology company.
This deal would put Pfizer into competition with Cerezyme, Genzyme’s biggest-selling product.

Dec 1 · 12:32:00 PM · Source: Company News Release
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Humana (HUM)

Humana Profit Up

Humana said Monday that it had third-quarter net income of $301.5 million, or $1.78 per share, compared with $183 million, or $1.09 per share, a year earlier. Revenue rose 8 percent to $7.72 billion.
Analysts had expected $7.82 billion in revenue.

Nov 2 · 1:01:00 PM · Source: Company News Release
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Aetna (AET)

Aetna Earnings, Revenues Up; Top Estimates

Aetna said today that its third-quarter net income climbed 18 percent to $326.2 million, or 73 cents a share, from 277.3 or 58 cents per share. Revenue rose 9% to 8,704.4 million from 7,981.4 million.
Results beat analysts' forecasts.

Oct 29 · 11:03:00 AM · Source: Company News Release
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

WellPoint Health Networks (WLP)

Wellpoint Profit Down, But Tops Estimates

Wellpoint said that third quarter earnings of $730.2 million, or $1.53 a share, down from $820.7 million, or $1.60 a share, a year earlier. Revenue rose 3.1% to $15.43 billion
Company's CEO said the nation's largest health insurer by members remains confident about the outlook for the current quarter and expects net growth of more than 400,000 national members in January.

Oct 28 · 10:46:00 AM · Source: Company News Release
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Glaxosmithkline Plc (GSK)

Glaxosmithkline Profit Up, Tops Estimates

Glaxosmithkline said its third quarter net income increased 30 percent to 1.34 billion pounds ($2.18 billion) from 1.03 billion pounds a year earlier. Third- quarter revenue advanced 15 percent to 6.76 billion pounds, from 5.88 billion pounds,
Revenues topped the 6.75 billion-pound analyst estimates.

Oct 28 · 10:17:00 AM · Source: Company News Release
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Merck (MRK)

Merck Earnings and Outlook Up

Merck & Co.'s (MRK) third-quarter profit more than tripled on a gain from the sale of the drug maker's stake in an animal-health joint venture, while a continued rebound in a blockbuster asthma drug helped overall sales inch higher.
For the three months ended Sept. 30, Merck reported net income of $3.4 billion, or $1.61 a share, up from $1.09 billion, or 51 cents a share, a year earlier. The latest quarter included a gain of $1.7 billion from Merck's sale of its 50% interest in the Merial animal-health joint venture to Sanofi-Aventis SA (SNY), which already owned the other half.

Oct 22 · 9:24:00 AM · Source: Wall Street Journal
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter


Previous · Next
Copyright © 2010 MarketBeast.com.
All rights reserved.